Eli Lilly to present data at European Society of Medical Oncology Congress

Eli Lilly and Co. will present data at the European Society of Medical Oncology’s (ESMO) 2016 Congress in Copenhagen from a number of clinical studies that will serve to further strengthen the development of its diverse clinical cancer portfolio.

"Lilly's three-pillar oncology R&D strategy is unique," Lilly Oncology Senior Vice President of Product Development and Medical Affairs Dr. Richard Gaynor said. "While there's no single therapy or one way to attack tumor cell growth and progression that works for all patients, as an industry we are continually learning how some approaches work better than others in certain patient populations."

Gaynor said Lilly is aggressively approaching cancer therapy development from many angles, including the study of combination therapies across the three pillars to address tumor heterogeneity and drug resistance.

Data to be presented at this year's ESMO Congress demonstrates their intent to bring forth best-in-class treatment options to help patients around the world. Included in the presentations will be research on CDK4 and CDK 6 inhibitor abemaciclib; olaratumab, the antibody that blocks PDGFRa; the multi-targeted antifolate pemetrexed; the VEGF Receptor 2 antagonist, ramucirumab; and the antibody that blocks EGFR, necitumumab.